FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment
The FDA has approved Isembyld (apitegromab-mstn), the first muscle-targeted therapy for spinal muscular atrophy (SMA) that works alongside existing SMN-targeted treatments. The approval is based on positive Phase 3 SAPPHIRE study results showing clinically meaningful improvements in motor function. This milestone represents a shift from slowing SMA progression to improving patient function and quality of life.